**Supplementary material**

**Table E1. Overview of the medication use.**

|  |  |
| --- | --- |
| **Type of medication****(with specified combinations)** | **Number of patients (% of total sample)** |
|  |  |
|  |  |
| **Monotherapy** | **14 (2.1)** |
| SABA | 7 (1.0) |
| SAMA | 2 (0.3) |
| LABA | 0 (0.0) |
| LAMA | 1 (0.1) |
| ICS | 4 (0.6) |
|  |  |
| **Bronchodilator combinations\*** | **31 (4.6)** |
| SABA/SAMA | 12 (1.8) |
| LABA/SABA | 1 (0.1) |
| LAMA/SABA | 1 (0.1) |
| LABA/LAMA | 5 (0.7) |
| LABA/SAMA | 2 (0.3) |
| LABA/SAMA/SABA | 2 (0.3) |
| LAMA/SABA/SAMA | 3 (0.4) |
| LABA/LAMA/SABA | 3 (0.4) |
| LABA/LAMA/SABA/SAMA | 2 (0.3) |
|  |  |
| **ICS containing combinations\*** | **569 (84.5)** |
| ICS/SABA | 8 (1.2) |
| ICS/SAMA | 5 (0.7) |
| ICS/LABA | 75 (11.1) |
| ICS/LAMA | 5 (0.7) |
| ICS/SABA/SAMA | 13 (1.9) |
| ICS/LABA/SABA | 69 (10.3) |
| ICS/LAMA/SABA | 6 (0.9) |
| ICS/LABA/SAMA | 24 (3.6) |
| ICS/LAMA/SAMA | 1 (0.1) |
| ICS/LABA/LAMA | 73 (10.8) |
| ICS/LABA/SABA/SAMA | 77 (11.4) |
| ICS/LAMA/SABA/SAMA | 5 (0.7) |
| ICS/LABA/LAMA/SABA | 112 (16.6) |
| ICS/LABA/LAMA/SAMA | 7 (1.0) |
| ICS/LABA/LAMA/SABA/SAMA | 89 (13.2) |
|  |  |
| **Maintenance OCS** | **149 (22.1)** |
| **Missing** | **59 (8.8)** |

Values are presented as frequencies (percentages).
*Abbreviations*. SABA: short acting beta agonist; SAMA: short acting muscarinic antagonist; ICS: inhalation corticosteroids; LAMA: long acting muscarinic antagonist; LABA: long acting beta agonist; OCS: oral corticosteroids. \*the presented combinations include both single-inhaler combination therapies as well as multi-inhaler combination therapies